ANI Pharmaceuticals Company Insiders
| ANIP Stock | USD 65.48 0.08 0.12% |
ANI Pharmaceuticals' insiders are aggressively selling. The analysis of insiders' sentiment of trading ANI Pharmaceuticals stock suggests that virtually all insiders are panicking at this time. ANI Pharmaceuticals employs about 642 people. The company is managed by 26 executives with a total tenure of roughly 166 years, averaging almost 6.0 years of service per executive, having 24.69 employees per reported executive.
| Arthur Przybyl CEO CEO and President and Director |
| Robert Brown Chairman Chairman of the Board |
ANI Pharmaceuticals' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-04-12 | Meredith Cook | Disposed 250 @ 67.79 | View | ||
| 2024-04-01 | Chad Gassert | Disposed 20000 @ 67.25 | View | ||
| 2024-03-11 | Stephen P Carey | Disposed 7787 @ 65.55 | View | ||
| 2024-03-08 | Nikhil Lalwani | Disposed 16292 @ 67.13 | View | ||
| 2024-03-07 | Muthusamy Shanmugam | Disposed 15085 @ 66.35 | View | ||
| 2024-03-06 | Nikhil Lalwani | Disposed 28965 @ 65.52 | View | ||
| 2024-03-05 | Muthusamy Shanmugam | Disposed 10093 @ 65.35 | View | ||
| 2024-02-13 | Meredith Cook | Disposed 250 @ 56.04 | View | ||
| 2024-01-22 | Muthusamy Shanmugam | Disposed 5692 @ 55.95 | View | ||
| 2024-01-18 | Muthusamy Shanmugam | Disposed 9784 @ 55.3 | View | ||
| 2024-01-16 | Muthusamy Shanmugam | Disposed 5000 @ 55.63 | View | ||
| 2024-01-12 | Meredith Cook | Disposed 250 @ 56.43 | View | ||
| 2023-12-18 | Muthusamy Shanmugam | Disposed 13026 @ 52.44 | View | ||
| 2023-12-15 | Muthusamy Shanmugam | Disposed 11974 @ 52.44 | View | ||
| 2023-12-11 | Meredith Cook | Disposed 250 @ 49.21 | View | ||
| 2023-11-16 | Muthusamy Shanmugam | Disposed 6448 @ 51.66 | View | ||
| 2023-11-15 | Krista Davis | Disposed 2622 @ 53.81 | View | ||
| 2023-11-14 | Muthusamy Shanmugam | Disposed 22095 @ 53.17 | View | ||
| 2023-10-18 | Muthusamy Shanmugam | Disposed 6242 @ 57.78 | View |
Monitoring ANI Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
ANI |
ANI Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ANI Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that ANI will maintain a workforce of slightly above 640 employees by May 2024.ANI Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.0372 % which means that it generated a profit of $0.0372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0472 %, meaning that it created $0.0472 on every $100 dollars invested by stockholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/17/2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.07. At this time, ANI Pharmaceuticals' Total Current Liabilities is relatively stable compared to the past year. As of 04/17/2024, Liabilities And Stockholders Equity is likely to grow to about 949.6 M, while Non Current Liabilities Other is likely to drop slightly above 14.4 M.As of 04/17/2024, Common Stock Shares Outstanding is likely to grow to about 19.1 M, though Net Loss is likely to grow to (42.3 M).
ANI Pharmaceuticals Workforce Comparison
ANI Pharmaceuticals is rated fifth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 30,171. ANI Pharmaceuticals holds roughly 642 in number of employees claiming about 2.13% of equities under Health Care industry.
ANI Pharmaceuticals Profit Margins
The company has Profit Margin (PM) of 0.04 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.07 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.07.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.74 | 0.5043 |
|
|
ANI Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ANI Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ANI Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ANI Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.45 | 18 | 40 | 332,173 | 288,803 |
| 2023-09-01 | 0.1613 | 5 | 31 | 38,118 | 605,824 |
| 2023-06-01 | 0.6 | 6 | 10 | 41,190 | 116,823 |
| 2023-03-01 | 1.0588 | 18 | 17 | 377,764 | 52,511 |
| 2022-09-01 | 0.5 | 1 | 2 | 19,280 | 8,818 |
| 2022-06-01 | 2.75 | 11 | 4 | 124,533 | 7,661 |
| 2022-03-01 | 1.4286 | 10 | 7 | 228,290 | 28,368 |
| 2021-03-01 | 2.8 | 14 | 5 | 372,563 | 7,829 |
| 2020-06-01 | 1.1429 | 8 | 7 | 141,744 | 7,552 |
| 2020-03-01 | 0.3333 | 2 | 6 | 5,000 | 9,932 |
| 2019-06-01 | 0.2222 | 4 | 18 | 6,154 | 58,150 |
| 2019-03-01 | 1.3125 | 21 | 16 | 187,656 | 82,851 |
| 2018-09-01 | 1.0 | 1 | 1 | 28,688 | 28,688 |
| 2018-06-01 | 0.9474 | 18 | 19 | 127,725 | 140,617 |
| 2018-03-01 | 0.2813 | 9 | 32 | 80,460 | 278,468 |
| 2017-03-01 | 9.0 | 18 | 2 | 138,125 | 1,120 |
| 2016-12-01 | 1.0 | 2 | 2 | 5,458 | 5,458 |
| 2016-09-01 | 2.0 | 6 | 3 | 106,356 | 50,791 |
| 2016-06-01 | 7.0 | 21 | 3 | 157,575 | 2,602 |
| 2016-03-01 | 1.0 | 2 | 2 | 22,446 | 22,446 |
| 2015-12-01 | 1.5 | 3 | 2 | 7,000 | 4,820 |
| 2015-09-01 | 1.0 | 5 | 5 | 38,561 | 38,561 |
| 2015-06-01 | 3.0 | 24 | 8 | 113,282 | 31,704 |
| 2014-06-01 | 11.0 | 22 | 2 | 352,182 | 6,381 |
| 2014-03-01 | 0.3673 | 18 | 49 | 142,326 | 423,664 |
| 2013-12-01 | 1.2692 | 33 | 26 | 264,442 | 91,104 |
| 2013-09-01 | 2.4 | 24 | 10 | 1,484,193 | 35,040 |
| 2013-06-01 | 6.0 | 12 | 2 | 42,096,523 | 283,883 |
| 2009-12-01 | 6.0 | 12 | 2 | 240,700 | 0.00 |
| 2008-09-01 | 1.0 | 3 | 3 | 147,512 | 147,512 |
ANI Pharmaceuticals Notable Stakeholders
An ANI Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ANI Pharmaceuticals often face trade-offs trying to please all of them. ANI Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ANI Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
About ANI Pharmaceuticals Management Performance
The success or failure of an entity such as ANI Pharmaceuticals often depends on how effective the management is. ANI Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ANI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ANI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.03 | 0.03 | |
| Return On Capital Employed | 0.07 | 0.07 | |
| Return On Assets | 0.02 | 0.02 | |
| Return On Equity | 0.04 | 0.05 |
The data published in ANI Pharmaceuticals' official financial statements usually reflect ANI Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ANI Pharmaceuticals. For example, before you start analyzing numbers published by ANI accountants, it's critical to develop an understanding of what ANI Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceuticals space in which it operates.
Please note, the presentation of ANI Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ANI Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ANI Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ANI Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ANI Pharmaceuticals' management manipulating its earnings.
ANI Pharmaceuticals Workforce Analysis
Traditionally, organizations such as ANI Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ANI Pharmaceuticals within its industry.ANI Pharmaceuticals Manpower Efficiency
Return on ANI Pharmaceuticals Manpower
| Revenue Per Employee | 758.3K | |
| Revenue Per Executive | 18.7M | |
| Net Income Per Employee | 29.3K | |
| Net Income Per Executive | 722.3K | |
| Working Capital Per Employee | 583.1K | |
| Working Capital Per Executive | 14.4M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Earnings Share 0.85 | Revenue Per Share 27.044 | Quarterly Revenue Growth 0.397 | Return On Assets 0.0372 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.